Ranbaxy Lab misses out "first -day launch" of hypertension drug: Report

25 Sep 2012 Evaluate

Country’s largest drug-maker, Ranbaxy Laboratories, has missed out on the 'first -day launch' of its generic version of Novartis' best-seller hypertension drug Diovan in the US, as the company is yet to get the US food and Drug Administration's (FDA's) approval for the generic version of the drug, Valsartan, as mentioned in a media report. The company was scheduled to launch its drug on September 21, 2012, the day from when Diovan's patent expired.

The company has the exclusive rights to market the generic for 180 days, after emerging as the first company to successfully challenge Novartis' patent for Diovan. However, Sandoz, the generic arm of Novartis, unveiled Diovan HCT, its low-cost version of a combination of valsartan and hydrochlorothiazide with a licence from Novartis. Similarly, Mylan Inc too started selling the same low-cost combination drug, also on Friday.

Ranbaxy Laboratories, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×